Gersl V
Sb Ved Pr Lek Fak Karlovy Univerzity Hradci Kralove. 1993;36(1-2):35-44.
The effects of substances--which in the isolated preparations possess calcium channel and alpha-adrenoceptor blocking activity--on cardiac contractility (dP/dtmax. of the blood pressure in the left ventricle) were evaluated. Substances VUFB 17951 (0.046 and 0.46 mg/kg) and VUFB 17959 (0.045 and 0.45 mg/kg) were administered intravenously in rabbits in vivo in pentobarbital anaesthesia under the conditions of the paced and non-paced heart rate. VUFB 17951 induced dose-dependent, immediately after the administration onsetting, progressive and significant decrease in dP/dtmax. (max. 50.5% in the paced and 51.4% in the non-paced heart). The effects of substance VUFB 17959 were less marked. On the basis of the results obtained in the present study it is possible to consider the participation of more mechanisms of the action (inc. calcium-channel antagonistic ones) related to negative inotropic effects of the substances. The absence of significant differences in the reaction of dP/dtmax. between the paced and non-paced heart conditions may then indicate a presence of a direct cardiodepressant action of substances VUFB 17951 and 17959.
评估了在离体制剂中具有钙通道和α-肾上腺素能受体阻断活性的物质对心脏收缩性(左心室血压的dP/dtmax)的影响。在戊巴比妥麻醉下,于家兔体内,在有起搏和无起搏心率的条件下,静脉注射物质VUFB 17951(0.046和0.46mg/kg)和VUFB 17959(0.045和0.45mg/kg)。VUFB 17951在给药后立即引起剂量依赖性、进行性且显著的dP/dtmax降低(起搏心率时最大降低50.5%,非起搏心率时最大降低51.4%)。物质VUFB 17959的作用不太明显。根据本研究获得的结果,可以认为该物质的负性肌力作用涉及更多作用机制(包括钙通道拮抗机制)。在有起搏和无起搏心率条件下dP/dtmax反应无显著差异,这可能表明物质VUFB 17951和17959存在直接的心脏抑制作用。